How to Get Leqvio (Inclisiran) in Connecticut

What Is Leqvio and Why Does It Matter for Connecticut Patients

Leqvio (inclisiran) is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 inside hepatocytes, reducing LDL-receptor degradation and driving LDL-C out of the bloodstream. Unlike monoclonal antibodies such as alirocumab or evolocumab, inclisiran requires only two maintenance injections per year after the loading phase. The FDA approved it in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

In the pooled ORION-10 and ORION-11 phase 3 trials (combined N=3,457), inclisiran 284 mg reduced LDL-C by a time-averaged 51 percent versus placebo at 510 days, with a safety profile comparable to placebo [2]. The ACC/AHA 2022 Guideline on Nonstatin Therapies states that PCSK9 inhibitors are reasonable to consider when LDL-C remains above 70 mg/dL in very-high-risk ASCVD despite high-intensity statin plus ezetimibe [3]. Inclisiran fits that therapeutic niche while reducing injection burden from every two to four weeks (with monoclonal antibodies) to twice annually.

Connecticut cardiovascular disease rates mirror national trends. The CDC reports that heart disease is the leading cause of death in Connecticut, accounting for roughly 24 percent of all state deaths [4]. For patients who cannot achieve guideline-recommended LDL-C targets on statins alone, inclisiran represents one of the few approved options with a dramatically simplified dosing schedule.

Who Qualifies for a Leqvio Prescription in Connecticut

The FDA-approved indications are narrow but cover a substantial patient population. Qualifying diagnoses include:

• Heterozygous familial hypercholesterolemia (HeFH), confirmed by clinical criteria or genetic testing
• Clinical ASCVD, defined as a history of acute coronary syndrome, stable angina, coronary or peripheral arterial revascularization, stroke, or peripheral artery disease

Patients must also demonstrate elevated LDL-C despite maximally tolerated statin therapy, typically with or without ezetimibe. The ACC/AHA cholesterol guideline uses a threshold of LDL-C above 70 mg/dL in very-high-risk patients and above 100 mg/dL in high-risk patients as the decision point for adding a non-statin agent [3].

Connecticut Medicaid (HUSKY Health) covers inclisiran with prior authorization when documentation confirms the qualifying diagnosis and evidence of statin intolerance or inadequate statin response [5]. Commercial payers in Connecticut generally follow similar criteria. Most insurers require a 12-week trial of high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) with a documented fasting lipid panel showing persistent LDL-C elevation before approving inclisiran.

The HealthRX clinical team uses a four-gate eligibility check for Connecticut patients: (1) confirmed ASCVD or HeFH diagnosis with source documentation, (2) current or documented intolerance to high-intensity statin therapy, (3) fasting lipid panel from within the past 90 days showing LDL-C above the payer threshold, and (4) no active pregnancy or plans for pregnancy, since inclisiran's safety in pregnancy has not been established [1].

Labs Required Before Starting Leqvio

A fasting lipid panel is the single mandatory lab before prescribing inclisiran. Providers also typically order a comprehensive metabolic panel (CMP) to assess hepatic and renal function, since patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) were excluded from ORION-10 and ORION-11, and the drug's pharmacokinetics in that population remain less well characterized [2].

The complete standard pre-treatment lab panel for Connecticut patients at HealthRX includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Comprehensive metabolic panel (CMP-14)
• HbA1c if diabetes status is unknown
• TSH if hypothyroidism has not been excluded (secondary cause of elevated LDL-C)
• Lipoprotein(a) measurement when HeFH is the working diagnosis, per FH Foundation guidance [6]

Many Connecticut commercial labs, including Quest Diagnostics and LabCorp, have draw sites throughout Hartford, New Haven, Bridgeport, Stamford, and Waterbury. A telehealth provider can issue lab orders electronically; results are typically available within 24 to 72 hours. Baseline LDL-C is essential for payer prior authorization forms, and some insurers in Connecticut also require a repeat lipid panel 12 weeks after statin optimization to document inadequate response before approving inclisiran [7].

How to Get a Leqvio Prescription in Connecticut: Step by Step

Getting inclisiran in Connecticut follows a predictable sequence regardless of whether the prescribing visit is in-person or via telehealth.

Step 1. Initial consultation. Schedule a visit with a cardiologist, internist, NP, or PA licensed in Connecticut. Connecticut's telehealth statutes permit audio-video prescribing for new and established patients without a prior in-person requirement for most non-controlled medications, including inclisiran [8]. HealthRX conducts this visit over a HIPAA-compliant video platform in approximately 30 minutes.

Step 2. Record and lab review. The prescriber reviews prior statin therapy documentation, current lipid panel results, and the qualifying ASCVD or HeFH diagnosis. If labs are missing, orders are issued to a local draw site.

Step 3. Prior authorization submission. The prescriber or their office submits a PA request to the patient's insurer. Connecticut insurers are required under state law to respond to PA requests within 3 business days for non-urgent cases and 1 business day for urgent cases [9]. Commercial PA approval rates for inclisiran have improved since 2022 as clinical guidelines have been updated.

Step 4. Specialty pharmacy dispensing. Inclisiran is distributed through a limited specialty pharmacy network. Once PA is approved, the specialty pharmacy ships the drug to the patient's home or directly to the provider's office. Injection must be administered by a healthcare professional; patients cannot self-inject.

Step 5. In-office or clinic injection. The first dose (day 1) and second dose (day 90) are administered by a healthcare provider. Subsequent doses follow every 6 months [1]. HealthRX coordinates with Connecticut-based infusion centers or primary care offices for injection administration when the prescribing visit is remote.

Step 6. Follow-up lipid panel. A repeat fasting lipid panel at approximately 90 days after the first injection confirms LDL-C response. ORION-10 showed LDL-C reductions of 52.3 percent at day 90, with sustained effect through 510 days [2].

Telehealth Prescribing for Leqvio in Connecticut

Connecticut fully permits telehealth prescribing of inclisiran. The state's telehealth statute (Conn. Gen. Stat. § 38a-499b) requires that telehealth services meet the same standard of care as in-person services but imposes no blanket prohibition on new-patient telehealth prescribing for non-controlled drugs [8]. Inclisiran is not a controlled substance, so DEA in-person evaluation rules do not apply.

A Connecticut-licensed telehealth prescriber can complete the clinical assessment, review uploaded records, and submit the PA electronically. The limitation is the injection step: inclisiran cannot be self-administered. The telehealth provider must arrange a local injection site. HealthRX maintains a network of cooperating Connecticut clinics in Hartford County, New Haven County, Fairfield County, and Tolland County to cover this gap.

Published data support telehealth cardiology for lipid management. A 2022 analysis in the Journal of the American Heart Association found that telehealth lipid management produced LDL-C reductions statistically equivalent to in-person care in patients with ASCVD [10]. Telehealth removes geographic barriers for patients in rural Connecticut counties such as Windham and Litchfield, where access to cardiologists is limited.

Leqvio Pharmacies in Connecticut: Specialty and 503A Options

Inclisiran is distributed through a specialty pharmacy model. Major specialty pharmacies dispensing Leqvio to Connecticut patients include Accredo (Express Scripts), CVS Specialty, and Biologics by McKesson. These pharmacies coordinate benefit verification, PA support, and cold-chain shipping directly to the provider's office or a designated clinical site.

Connecticut also has licensed 503A compounding pharmacies. Under federal and Connecticut law, a 503A pharmacy may compound inclisiran for an individual patient with a valid prescription from a licensed prescriber when a documented clinical need exists [11]. Compounded inclisiran is not FDA-approved and may differ in formulation from the brand product. Patients considering a 503A compounded product should discuss the regulatory distinctions with their prescriber.

For patients using Connecticut Medicaid (HUSKY A, HUSKY C, or HUSKY D), the specialty pharmacy must be enrolled in the Connecticut Medicaid preferred drug list (PDL) program. The CT DSS Preferred Drug List designates inclisiran as a non-preferred agent requiring PA, meaning approval is available but not automatic [5]. Patient assistance through the Novartis HEART program is available for commercially uninsured or underinsured Connecticut patients and can reduce out-of-pocket cost to as low as $0 per month for eligible individuals [12].

Prior Authorization in Connecticut: What Documentation to Prepare

Prior authorization for inclisiran in Connecticut typically requires the following documentation package regardless of payer:

• Diagnosis codes: E78.01 (HeFH) or applicable ASCVD ICD-10 code (I25.10, I63.9, etc.)
• Fasting LDL-C result from within 90 days showing elevation above payer threshold
• Documentation of current high-intensity statin therapy or written explanation of statin intolerance with a trial of at least two statins
• Clinical notes confirming ASCVD history or genetic/clinical FH diagnosis
• Prescriber's statement that ezetimibe has been trialed or is contraindicated (some payers)

Connecticut commercial payers, including Anthem BCBS CT, Aetna, and UnitedHealthcare, each publish their own clinical criteria. Anthem CT, for example, requires LDL-C above 70 mg/dL in ASCVD patients on maximally tolerated statin therapy and documentation that a PCSK9 inhibitor has either failed or is not accessible before approving inclisiran in some plan tiers [7]. Providers should pull the specific plan's medical policy prior to submission to avoid avoidable denials.

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol explicitly states: "For very high-risk patients, if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy and ezetimibe, addition of a PCSK9 inhibitor is reasonable" [3]. Quoting this guideline language directly in a PA letter strengthens the clinical rationale.

Appeals are possible when initial PA is denied. Connecticut law requires insurers to offer an expedited appeal process. The CT Insurance Department's Consumer Affairs division can be contacted if an insurer fails to respond within statutory timeframes [9].

How Long Until Inclisiran Is Received in Connecticut

From initial consultation to first injection, the typical timeline in Connecticut runs 2 to 6 weeks. The breakdown is approximately:

• Telehealth or in-person visit: same day to 5 business days for scheduling
• Lab results: 1 to 3 business days
• PA decision: up to 3 business days under CT law (urgent) or up to 72 hours (standard) [9]
• Specialty pharmacy dispensing and shipping: 3 to 7 business days after PA approval
• Injection appointment: 1 to 5 business days after drug arrives

Delays most commonly occur at the PA stage if documentation is incomplete or if the prescribing office must chase prior statin trial records. HealthRX's PA coordination team pre-audits the documentation package before submission, which reduces first-submission denial rates. When PA is denied and appealed, total time to first injection may extend to 8 to 12 weeks.

Who Can Prescribe Leqvio in Connecticut

Any Connecticut-licensed prescriber with authority to write for prescription-only medications may prescribe inclisiran. This includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO)
• Advanced practice registered nurses (APRN) with prescriptive authority
• Physician assistants (PA-C) with a supervising physician agreement, per Connecticut law

Connecticut APRNs with a controlled substance registration and a collaborating physician agreement have independent prescriptive authority for Schedule II through V and non-controlled drugs [8]. Inclisiran, as a non-controlled prescription drug, falls squarely within an APRN's prescriptive scope. This matters for telehealth access: HealthRX APRNs licensed in Connecticut can initiate an inclisiran prescription without a physician co-signature in most clinical contexts.

Cardiology specialist oversight is not legally required but is clinically advisable for patients with complex ASCVD, recent ACS, or ambiguous FH diagnosis. The FH Foundation recommends referral to a lipid specialist or preventive cardiologist for patients with LDL-C above 190 mg/dL or a possible homozygous FH presentation [6].

Monitoring After Starting Inclisiran

After the first injection, clinical monitoring focuses on LDL-C response and tolerability. The Leqvio prescribing label recommends a fasting lipid panel 90 days after initiation and periodically thereafter [1]. In ORION-10, 73.9 percent of patients achieved LDL-C below 70 mg/dL at month 17 with inclisiran versus 9.7 percent with placebo, a difference of 64.2 percentage points (P<0.001) [2].

Injection-site reactions occurred in 8.2 percent of inclisiran-treated patients in pooled ORION data versus 1.8 percent with placebo, making them the most common drug-specific adverse event [2]. Reactions are typically mild, transient, and localized. No dose adjustment is required for mild to moderate hepatic impairment. Patients with severe renal impairment should be monitored more closely given limited phase 3 data in that population [1].

Statin and ezetimibe therapy should continue unchanged when inclisiran is added. The drug is additive to, not a replacement for, existing lipid-lowering therapy. Annual lipid panels are sufficient once LDL-C is confirmed at goal, though some cardiologists prefer semi-annual checks aligned with injection visits [3].